Literature DB >> 6699870

5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation.

H D Showalter, J L Johnson, L M Werbel, W R Leopold, R C Jackson, E F Elslager.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6699870     DOI： 10.1021/jm00369a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  16 in total

1.  Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.

Authors:  S K Williamson; J J Crowley; R Livingston; A Hantel; J H Doroshow
Journal:  Invest New Drugs       Date:  1992-04       Impact factor: 3.850

2.  The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.

Authors:  M A Graham; D R Newell; B J Foster; A H Calvert
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck. A Southwest Oncology Group trial.

Authors:  S A Taylor; J Benedetti; D Schuller; S P Richman; G O Broun; A Hantel
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

4.  Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology.

Authors:  S G Allan; J Cummings; S Evans; M Nicolson; M E Stewart; J Cassidy; M Soukop; S B Kaye; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Phase II trial of piroxantrone in metastatic gastric adenocarcinoma.

Authors:  R Pazdur; B Bready; A J Scalzo; J E Brandof; D R Close; S Kolbye; R J Winn
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.

Authors:  M M Zalupski; J Benedetti; S P Balcerzak; L F Hutchins; R J Belt; A Hantel; J W Goodwin
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

7.  Pharmacokinetics, cerebrospinal fluid penetration, and metabolism of piroxantrone in the rhesus monkey.

Authors:  S L Berg; F M Balis; K S Godwin; D G Poplack
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

8.  A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study.

Authors:  T R Jenkins; C Tangen; J S Macdonald; G Weiss; R Chapman; A Hantel
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

9.  Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).

Authors:  S K Frank; D A Mathiesen; M Szurszewski; M J Kuffel; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

10.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.